Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

MIT engineers create robotic thread to break blockages in brain's blood vessels
MIT engineers create robotic thread to break blockages in brain's blood vessels
WASHINGTON, Aug.
U.S. researchers develop new skin patch for cancer treatment
U.S. researchers develop new skin patch for cancer treatment
SAN DIEGO, Aug.
FDA green light for Fasenra
FDA green light for Fasenra
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE), Astr...
Study finds moderate red wine drinking may be good to gut health
Study finds moderate red wine drinking may be good to gut health
LONDON, Aug.
Veeva Introduces Quality Risk Management in Vault QMS
Veeva Introduces Quality Risk Management in Vault QMS
Veeva Systems (NYSE.
AstraZeneca lupus drug shows promise after set-back last year
AstraZeneca lupus drug shows promise after set-back last year
(Reuters) - AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage study, an encouraging sign after it failed to meet its ma...
FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients
FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients
(Reuters) - The U.
U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
(Reuters) - A U.
FDA Approves Ixekizumab for Ankylosing Spondylitis Indication
FDA Approves Ixekizumab for Ankylosing Spondylitis Indication
Officials with the FDA have approved Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL for the treatment of active ankylosing spondylitis (AS), also known as radiographic axial spond...
OxyContin maker negotiating settlement worth a reported $12B
OxyContin maker negotiating settlement worth a reported $12B
Purdue Pharma and the thousands of state and local governments suing the maker of OxyContin over the nation's deadly opioid crisis are negotiating a $10 billion to $12 billion settlement under whi...
Lilly’s atopic dermatitis drug hits endpoints
Lilly’s atopic dermatitis drug hits endpoints
Eli Lilly and Incyte have announced that Olumiant (baricitinib) met the primary endpoint in BREEZE-AD7, the third pivotal Phase III trial in the BREEZE-AD program to be completed in 2019.
Amgen to buy Celgene’s Otezla in $13.4bn deal
Amgen to buy Celgene’s Otezla in $13.4bn deal
Amgen agreed to buy Celgene’s Otezla, a treatment for psoriasis and Behçet’s disease, for $13.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand